SEC 13F Intelligence

Managers / Q3 2025 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$132M
Q3 2025
Positions
69
Filings on Record
39
2019–present window
Filed
Nov 13, 2025
original filing

Summary

Birchview Capital, LP reported $132M in U.S.-listed holdings across 69 positions for Q3 2025.

Its largest position, KLAC, represents 17.8% of the portfolio.

Compared with Q2 2025, the fund opened 8 new positions and exited 10.

Portfolio Metrics

Turnover
+6.8%
vs prior filed quarter
Top-10 Concentration
+55.5%
share of reported value
Largest Position
+17.8%
Kla Corporation
New / Exited
8 / 10
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 84.8%Other: 12.5%ADR: 2.5%ETP: 0.2%
  • Common Stock · 84.8% · $112M
  • Other · 12.5% · $17M
  • ADR · 2.5% · $3M
  • ETP · 0.2% · $208,477

Quarter-over-Quarter Changes full breakdown →

vs Q2 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CMPXCOMPASS THERAPEUTICS INCNEW+872.9K872.9K+$3M$3M
BCYCBICYCLE THERAPEUTICS PLCNEW+154.0K154.0K+$1M$1M
VYGRVOYAGER THERAPEUTICS INCNEW+134.9K134.9K+$630,067$630,067
AVTXAVALO THERAPEUTICS INCNEW+31.0K31.0K+$394,010$394,010
GHGUARDANT HEALTH INCNEW+6.0K6.0K+$374,880$374,880
PHARVARIS N VNEW+14.8K14.8K+$370,433$370,433
NKTRNEKTAR THERAPEUTICSNEW+4.0K4.0K+$228,795$228,795
HEALTHCARE SELECT SECTOR SPDR FUNDNEW+1.5K1.5K+$208,477$208,477

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2025

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1KLACKLA CORPORATIONhistory →COM NEW17.82%$24M21.9K
2BMYBRISTOL-MYERS SQUIBB COhistory →COM10.79%$14M316.8K
3HTDCORCEPT THERAPEUTICS INChistory →COM4.22%$6M67.2K
4PROTHENA CORP PLCSHS4.05%$5M549.0K
5STOKSTOKE THERAPEUTICS INChistory →COM3.73%$5M210.0K
6UNIQURE NVSHS3.47%$5M78.7K
7OVVOVINTIV INChistory →COM3.28%$4M107.5K
8NBIXNEUROCRINE BIOSCIENCES INChistory →COM3.04%$4M28.7K
9ACADACADIA PHARMACEUTICALS INChistory →COM2.76%$4M171.0K
10PTGXPROTAGONIST THERAPEUTICS INChistory →COM2.41%$3M48.0K
11CMPXCOMPASS THERAPEUTICS INChistory →COM2.31%$3M872.9K
12PHRPHREESIA INChistory →COM2.04%$3M114.7K
13CSTLCASTLE BIOSCIENCES INChistory →COM1.90%$3M110.6K
14GPCRSTRUCTURE THERAPEUTICS INChistory →SPONS ADR1.65%$2M78.0K
15BIODESIX INCCOM1.63%$2M286.8K
16QDEL*QUIDELORTHO CORPhistory →COM1.61%$2M72.5K
17AXGNAXOGEN INChistory →COM1.60%$2M119.1K
18AM6AMICUS THERAPEUTICS INChistory →COM1.51%$2M253.0K
19HROWHARROW HEALTH INChistory →COM1.46%$2M40.0K
20EQTEQT CORPORATIONhistory →COM1.42%$2M34.6K
21SLDBSOLID BIOSCIENCES INChistory →COM NEW1.38%$2M297.0K
22OLMAOLEMA PHARMACEUTICALS INChistory →COM1.29%$2M174.0K
23CYTKCYTOKINETICS INChistory →COM1.24%$2M30.0K
24ALKERMES PLCSHS1.13%$2M50.0K
25FHTXFOGHORN THERAPEUTICS INChistory →COM1.04%$1M281.7K
26NOVOCURE LTDORD SHS1.00%$1M102.1K
27UTHUNITED THERAPEUTICS CORPCOM0.95%$1M3.0K
28IMNMIMMUNOME INCCOM0.93%$1M105.0K
29MASI*MASIMO CORPCOM0.92%$1M8.3K
30BCYCBICYCLE THERAPEUTICS PLCSPONSORED ADS0.90%$1M154.0K
31TMCITREACE MEDICAL CONCEPTS INCCOM0.90%$1M176.9K
32KINIKSA PHARMACEUTICALS LTDCOM0.88%$1M30.0K
33OMGBPOUTSET MEDICAL INCCOM0.84%$1M78.6K
34INBXINHIBRX BIOSCIENCES INCCOM0.81%$1M31.7K
35DCGODOCGO INCCOM0.78%$1M764.1K
36NTLAINTELLIA THERAPEUTICS INCCOM0.78%$1M60.0K
37TVTXTRAVERE THERAPEUTICS INCCOM0.78%$1M43.1K
38PHATPHATHOM PHARMACEUTICALS INCCOM0.76%$1M85.0K
39SRRKSCHOLAR ROCK HOLDING CORPCOM0.73%$968,24026.0K
40XENEXENON PHARMACEUTICALS INCCOM0.64%$843,15021.0K
414XC1KALVISTA PHARMACEUTICALS INCCOM0.62%$816,06067.0K
42HALOHALOZYME THERAPEUTICS INCCOM0.56%$740,73410.1K
43AXSMAXSOME THERAPEUTICS INCCOM0.55%$728,7006.0K
44FCXFREEPORT-MCMORAN CL-BCL-B0.53%$707,68918.0K
45RAREULTRAGENYX PHARMACEUTICAL INCCOM0.50%$661,76022.0K
46PACBPACIFIC BIOSCIENCES OF CALIFORNIA INCCOM0.48%$640,000500.0K
47APGEAPOGEE THERAPEUTICS INCCOM0.48%$635,68016.0K
48ELUTELUTIA INCCOM0.48%$633,088711.2K
49VYGRVOYAGER THERAPEUTICS INCCOM0.48%$630,067134.9K
50ATECALPHATEC HOLDINGS INCCOM0.36%$479,82033.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.